Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in adults Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10191895" target="_blank" >RIV/00179906:_____/13:10191895 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/13:43875052

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in adults Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

Popis výsledku v původním jazyce

Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. Discussion: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agendaof national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and thefuture place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. Results: The use of c

Název v anglickém jazyce

Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in adults Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

Popis výsledku anglicky

Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. Discussion: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agendaof national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and thefuture place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. Results: The use of c

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Central European Journal of Public Health

ISSN

1210-7778

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

233-237

Kód UT WoS článku

000329004200013

EID výsledku v databázi Scopus

—